Triple therapy with radiation for children with midline glioma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of three drugs (temozolomide, anlotinib, and bemarituzumab) along with radiation therapy for children with a type of brain tumor called diffuse midline glioma. The goal is to see if this approach can help shrink or control the tumor when surgery cannot remove it completely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 3 and 18 years old.
- You have been diagnosed with diffuse midline glioma (a type of brain tumor).
- Your tumor could not be completely removed with surgery.
- You have not had any previous treatment for this tumor.
- You are in reasonable health, with normal blood counts and organ function.
- You agree to use effective birth control if you are of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ADI-PEG 20 combined with standard treatments (temozolomide and radiation) for children and young adults with newly diagnosed high-grade glioma. It aims to see if this combination is safe and effective.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
This trial tests a new way of giving radiation therapy for a type of brain tumor called diffuse midline glioma. It aims to see if splitting the radiation into smaller courses can help while reducing side effects.
This trial tests a modified herpes virus (M032) given directly into the brain tumor after standard radiation. The goal is to see if this virus can slow or stop the growth of diffuse midline glioma, a type of brain cancer.
Hear when a new Maintenance Treatment of Diffuse Midline Gliomas in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.